PDL BioPharma — Q3 2019 Earnings Presentation
14 slides from PDL BioPharma's earnings presentation, Nov 6, 2019
Slide 1: 2019 Third Quarter Financial Results Conference Call
PDL 2019 Third Quarter Financial Results Conference Call November 6, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual
Slide 3: Strong Operating Results
Strong Operating Results Oo Oo Oo Oo Q3-19 revenues exceed $44 million = Revenues were driven by sales growth from LENSAR and a favorable contribution from our royalty assets Both LENSAR revenue and cash flows from royalty assets are tracking ahead of our 2019 guidance YTD we reduced G&A by 16% whil
Slide 4: LENSAR: Innovation Driving Growth
LENSAR: Innovation Driving Growth o Record quarterly revenues of $8.1 million = 22% increase from Q3-18 = 9% increase from Q2-19 o YTD revenues of $22 million, up 27% YoY, on path to exceed 2019 guidance of $29 million o R&D investments build on position as a leading innovator for the treatment of c
Slide 5: LENSAR: Positioned for Sustained Growth
LENSAR: Positioned for Sustained Growth o Significant unmet need remains in the cataract surgery market = 70%-90% of patients who undergo cataract surgery have treatable, visually significant astigmatism, but it remains largely uncorrected = Almost 50% of postoperative cataract patients have unaccep
Slide 6: LENSAR GEN2: Disruptive New Technology
LENSAR GEN2: Disruptive New Technology o Development of GEN2, a compact, integrated, all-in-one femto-phaco workstation establishes LENSAR as the innovation leader = 1st femtosecond laser that can perform all cataract surgeries = Combines state-of-the-art benefits of LENSAR Laser System and ultrasou
Slide 7: Evofem: On Track to Resubmit NDA
Evofem: On Track to Resubmit NDA o Resubmission of Amphora® NDA for prevention of pregnancy is on track for Q4-19 o Factors provide confidence in approach to gaining FDA approval = Phase 3 AMPOWER is designed to exceed the number of women and cycles agreed to by FDA; trial achieved strong clinical r
Slide 8: Evofem: Multiple Near-Term Catalysts
Evofem: Multiple Near-Term Catalysts Nov-19 Q4-19 Q2-20 2020 Topline data readout from Phase 2b AMPREVENCE trial + Evaluating Amphora for prevention of chlamydia, with secondary endpoint of prevention of gonorrhea * Opportunity to expand label for dual indication contraceptive with built-in ST| prev
Slide 9: PDL: Strong Balance Sheet
PDL: Strong Balance Sheet o Liquid balance sheet with $294 million in cash o Royalty rights valued at $314 million; $465 million expected in future royalty rights cash payments through 2026 o Completed $100 million share repurchase program = Largest single investment in 2019 on a YTD basis and demon
Slide 10: Third Quarter 2019 Financials (unaudited)
Third Quarter 2019 Financials (unaudited) Three Months Ended Nine Months Ended ‘September 30, ‘September 30, (in thousands, except per share amounts) 2019 2018 2019 2018 Product revenue, net § 20345 _§ 2437 _§ 64868 _§ 79.472 Royalty rights ~ change in fair value 23,885 42.184 (4270 66.117 Royalties
Slide 11: Third Quarter 2019 Financials (unaudited)
11 Third Quarter 2019 Financials (unaudited) GAAP to Non-GAAP Net (Loss) Income Reconciliation (in thousands) ‘GAP net Joss) income attbuted to PDL's shareholders, as reported Adjustments: Markto-market adjusimentto firvalue -royaltyassets Markto-market adjusim ents to equityaffiate -common stock No
Slide 12: Third Quarter 2019 Financials (unaudited)
Third Quarter 2019 Financials (unaudited) Consolidated balance sheet data (in thousands) Cash and cash equivalents Notes receivable Royalty rights - at fair value Investment in equity affiliate Intangible assets, net Total assets Convertible notes payable Total stockholders' equity September 30, Dec
Slide 13: On Track to Exceed 2019 Guidance
On Track to Exceed 2019 Guidance o Affirming guidance for Noden product revenue expected to be $50 million to $55 million o Increasing expectations for LENSAR product revenue and cash royalties o LENSAR product revenue expected to exceed $29 million = Up from prior guidance of $27 million to $29 mil
Slide 14: Questions & Answers
PDL Questions & Answers